Posted on Thursday, April 12, 2018 By Erik Miljan
The new website offers visitors rich insights into the Company’s lead stem cell product, StemPlanTM, and applied expertise of the therapeutic and biotechnology applications of stem cells.BioDivide Limited (“BioDivide” or the “Company), a world leader in stem cell and regenerative medicines, products, tools, technologies and services, announced today the launch of its new website. The Company’s unique and innovative stem cell product, StemPlan, is a feature in the new website. StemPlan, is a stem cell therapy approved by the UK Veterinary Medicine’s Directorate that uses a non-invasive proprietary and innovative method of collecting stem cells. Not offered by any other company, StemPlan uniquely provides horse owners with readily available stem cell therapy when they need it most.
The new website offers a comprehensive understanding of stem cell therapy and how regenerative medicine leads to repair of injured or diseased tissue to restore normal function. The website also provides a complete overview of the Company’s GMP facilities and service offerings engineered to harness the power of stem cells and regenerative medicine. BioDivide’s commitment to quality and biologicals manufacturing capabilities are emphasised in the new site. The new website goes live today and is located at http://www.biodivide.com
“We are excited about our new website launch and the comprehensive information it provides about BioDivide’s exclusive products and services” said Dr Erik Miljan, BioDivide’s founder and Chief Executive Officer. “We believe that this new site provides valuable information about stem cell therapy to the public and our customers”.
“Not all stem cells are the same. Manufacturing a top quality stem cell product requires understanding the biology and process that will give you different characteristics, whether consistency, purity or potency, added Dr Miljan.”
BioDivide provides the highest quality stem cell supportive therapy products and services. The Company’s quality systems incorporate needle-to-needle traceability for the complete supply chain. Visitors are encouraged to explore the new website to learn more about stem cells and regenerative medicine.
Posted on Tuesday, December 12, 2017 By Shannon Blaszko
Oxford, UK: Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, has taken laboratory and office space at The Oxford Science Park. In its new premises on the Park, Immunocore will be focused on the development of immunotherapies for infectious diseases, complementing its cancer research at Milton Park in Oxford
Posted on Wednesday, May 17, 2017 By Lindsey Brown
Innovation Forum Leaders Conference 2017 - 'Convergence in Bio-innovation' - 4-5 December 2017, Oxford
The Innovation Forum Leaders Conference 2017 will take place on 4th and 5th December in Oxford, UK and is an invitation only, world-leading conference supporting industry-academic collaborations and investment for early-stage ventures. Apply for an invitation. Our global conference will bring together over 400 delegates from the healthcare, biotechnology and life science sectors: Academics, start-ups, early stage ventures, SMEs, large pharmaceutical companies, prominent investors and top innovators. CEOs, prominent investors and top innovators will deliver keynote speeches and head discussions on the latest trends in therapeutics, cleantech and medtech as part of our 2-day extensive programme of presentations and workshops.